Liperial

Fenofibrate, the active ingredient in Liperial, is a fibrate presented as an oral tablet for oral use. It lowers elevated triglyceride levels and is used as part of lipid‑modifying therapy in adults with certain dyslipidemias. It works by activating PPARα, increasing the breakdown of triglyceride‑rich particles and modestly raising HDL‑cholesterol.

GNH USA supplies Liperial as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Fenofibrate is indicated for lipid disorders that involve elevated triglycerides and mixed dyslipidemia. - Hypertriglyceridemia: reduces plasma triglyceride concentrations. - Mixed dyslipidemia: lowers triglycerides and modestly increases HDL‑cholesterol. - Primary hypercholesterolemia (adjunct therapy): used together with statins to improve overall lipid profile.

Fenofibrate may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Abdominal discomfort or pain. - Nausea or dyspepsia. - Headache. - Back pain or myalgia. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Rhabdomyolysis, especially when combined with statins. - Severe hepatotoxicity or liver failure. - Acute pancreatitis. - Life‑threatening allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome. - Blood clotting abnormalities, including elevated INR when used with warfarin.

Before initiating fenofibrate therapy, several safety considerations should be reviewed. - Liver function monitoring: assess baseline hepatic enzymes and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in elderly patients. - Gallstone risk: avoid in patients with known biliary disease or gallstones. - Hypothyroidism caution: ensure thyroid status is controlled before use. - Drug‑induced myopathy vigilance: monitor for unexplained muscle pain or weakness. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Fenofibrate can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of rhabdomyolysis. - High‑dose statins (e.g., rosuvastatin): may precipitate severe myopathy. - Cyclosporine: can raise fenofibrate plasma levels, increasing toxicity. - Warfarin: fenofibrate may potentiate anticoagulant effect, raising INR.

Moderate Interactions (Monitor Closely): - Oral anticoagulants (other than warfarin): monitor coagulation parameters. - Antidiabetic agents (e.g., insulin, sulfonylureas): fenofibrate may affect glucose control. - Bile‑acid sequestrants (e.g., cholestyramine): may reduce fenofibrate absorption. - Niacin: combined therapy can increase risk of hepatotoxicity.